NCAPD3

Across TCGA pan-cancer cohorts, NCAPD3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of NCAPD3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where NCAPD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NCAPD3 is over-expressed in tumor.

LSCC, HNSC, and LUAD are the cancer types where NCAPD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NCAPD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.666	<.001	9	view →
HNSC	Male	III,IV	+0.329	<.001	9	view →
LUAD	All	III,IV	+0.586	<.001	8	view →
CCRCC	All	All	+0.384	<.001	5	view →
PDAC	All	All	+0.403	.006	4	view →
OV	All	All	+0.738	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

NCAPD3–LSCC

Open the LSCC breakdown →